Research
Hormonal
Important parameters for choosing glucose-lowering agents include drug efficacy, risk of hypoglycemia, effect on weight, side effects, and cost.
Practitioners should evaluate these parameters when selecting glucose-lowering agents.
StrongSupportsmedium confidence
The American Diabetes Association/European Association for the Study of Diabetes Position Statement... lists drug efficacy, risk of hypoglycemia, effect on weight, side effects, and cost as important parameters to consider when choosing GLAs.
Why this rating
The claim is based on a recognized position statement.
Source
Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back
Ofri Mosenzon et al. · Diabetes Care · 2016
DOI 10.2337/dcs15-3003
otherCited 22×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →